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IS THE NATIONAL PHARMACEUTICAL POLICY, 2012
REALLY CHEERING THE PHARMA?
Dipika Jain*
The National Pharmaceutical Policy was approved by the Cabinet and notified in 2012. Based on this policy, a
new Drugs Price Control Order was notified in May, 2013. As a result, several drugs will come within the ambit
of price control under the National list of Essential Medicines (NLEM). The primary purpose of NLEM is to
facilitate the rational use of medicines which will allow for cost effective, safe and drugs with efficacy. This paper
critically evaluates the provision on exclusion of patented drugs in the recent National Pharmaceutical Policy, 2012
from the Drug Pricing Policy for five years. The policy states “Drugs patented under the Indian Patents Act, 1970
and which have been made as a result of indigenous products or process have been exempted from price control for a
period of five years.” Further, a formulation involving a new delivery system developed through indigenous R&D
would be eligible for exemption from price control for a period of five years from the date of its market approval in
India. While this exclusion may have been designed keeping the opportunity for innovation for pharmaceutical
companies, however, given the critical situation of HIV/AIDSs medication, cancer drugs, tuberculosis etc., it is
pertinent to have these drugs under price control well before the prescribed period of five years. This paper argues that
this provision of the NLEM, 2012 contravenes the main objective of this policy and in turn violates the
Constitutional right to life and health of millions of people who need these patented lifesaving drugs, especially the
people living with HIV/AIDS (PHLAs).

Introduction
Access to essential drugs is a pressing concern in India today. This concern was in part exacerbated
by India’s transition from a process patent regime to a product patent one in 2005.1 Essential drugs
like the antiretroviral (‘ARV’) medicines for HIV/AIDS treatment and anti-cancer drugs are likely
to become unaffordable due to implementation of the product patent in the Indian Patent Act,
2005.2 The changes are likely to result in grave shortage in supplying ARV drugs to people in poor
countries3 and may encourage pharmaceutical company to prioritize revenues above the genuine
needs of public health.4 There are a few flexibilities available within Trade Related Intellectual
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Ministry of Health and Family Welfare Government of India, REPORT OF NATIONAL
COMMISSION ON MACRO ECONOMICS AND HEALTH (2005), page 6, available at
http://www.who.int/macrohealth/action/Report%20of%20the%20National%20Commission.pdf
2

Sorcha O’Carroll, Importing Indian Generic Drugs Following TRIPS: Case Studies from Zambia and Kenya, available
at http://www.mcmillan.ca/Files/SOCarroll_ImportingIndianGenericDrugs.pdf
3

See Cecilia Oh, TRIPS and Pharmaceuticals: A Case of Corporate Profits over Public Health, THIRD WORLD
NETWORK, Aug.-Sept. 2000, available at www.twnside.org.sg/title/twr120a.htm.
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Property Rights Agreement under the WTO regime (TRIPS). Beyond the patent regulations and
other available flexibilities in the national and international legislations, drug pricing is another
available ex post remedy to regulate access essential drugs by ensuring affordability.
Drug pricing is crucial towards making drugs affordable to ordinary citizens. Many price control
policies have been introduced in India from time to time.5 These policies were driven by the twin
objective of controlling the prices of essential (and later, bulk) drugs but also sought to
simultaneously ensure the availability of these drugs and to meet the requirements of the industry
for cost effective production, invention and capacity building.6
However, post-liberalization in 2002, a new pricing policy for pharmaceuticals was presented
which sought to liberalize the prices control further.7 This 2002 Policy was challenged in the High
Court at Karnataka and the Court issued a stay on the implementation of the policy on 12.11.2002.8
The Government challenged this order in the Supreme Court. The Apex Court vacated the stay
but directed the Government to devise suitable criteria to make sure that essential, lifesaving drugs
remained under price control.9 It also directed the Government to review these drugs until May,
2003.10 Therefore, the Drug Policy of 1994 remained in effect.
The All India Drug Action Network (AIDAN), along with other NGOs, filed a PIL in 2003 before
the Supreme Court, challenging the Government’s drug pricing policy.11 The main plea of this
public interest litigation was to ensure that the prices of essential drugs remain within the reach of

Id. In India, the first drug pricing policy was implemented in 1963 under the Defence of India Act. The
other are-the Drugs (Prices Control) Order of 1966, the Drugs (Prices Control) Order of 1970, issued under
the “Essential Commodities Act 1955 by declaring drugs to be essential commodities under the EC Act,
1955; the Drugs (Prices Control) Order of 1979 and Drugs (Prices Control) Order, 1987 were issued
following the declaration of Drug Policy, 1978 and Drug Policy 1986.
5

6

Supra note 4.

7

Supra note 4.

NATIONAL PHARMACEUTICALS PRICING POLICY, 2012 (7th December, 2012), available at
http://www.pharmaceuticals.gov.in/NPPP2012.pdf
8

9

Supra note 8.

10

Supra note 8.

S Srinivasan, A network for the rational and ethical use of drugs, Indian Journal of Medical Ethics, 11
January 2013, available at http://www.issuesinmedicalethics.org/121di013.html
11

See also Medicine Prices shouldn’t rise: Supreme Court, THE ECONOMIC TIMES, Nov 17, 2011 available at
http://articles.economictimes.indiatimes.com/2011-11-17/news/30410046_1_drug-pricing-policyessential-medicines-prices-control
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the common man.12 The Government set up a Committee in November 2004 to investigate the
options and alternatives of price control and related issues and accordingly make suggestions to
ensure the availability of essential, lifesaving drugs at affordable prices.13 This Committee offered
its suggestions in September 2005.14
In the meanwhile, the Ministry of Health and Family Welfare revised the list of drugs and notified
the new National List of Essential Medicine (NLEM), 2011.15 Due to concerns raised by various
stakeholders and difference between Ministries, the 2011 list was replaced by the new NLEM,
2012. This list consists of “those medicines that satisfy the priority healthcare needs of majority of
the population.”16

The National Pharmaceutical Policy, 2012
The National Pharmaceutical Policy was approved by the Cabinet and notified in 2012.17 Based on
this policy, a new Drugs Price Control Order was notified in May, 2013. A list of several drugs will
come within the ambit of price control called the National list of Essential Medicines (NLEM).
The primary purpose of NLEM is to facilitate the rational use of medicines which will allow for
cost effective, safe and drugs with efficacy.

18

This paper critically evaluates the provision on

exclusion of patented drugs in the recent National Pharmaceutical Policy, 2012 from the Drug
Pricing Policy for five years. The policy states “Drugs patented under the Indian Patents Act, 1970 and
which have been made as a result of indigenous products or process have been exempted from price control for a period
of five years.” Further, a formulation involving a new delivery system developed through indigenous
R&D would be eligible for exemption from price control for a period of 5 years from the date of

Medicine Prices shouldn’t rise: Supreme Court, IBNLIVE, 18 November 2011, available at
http://ibnlive.in.com/news/medicine-prices-shouldnt-rise-supreme-court/203413-17.html
12

13

Id.
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Supra note 12.
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Supra note 12.

NATIONAL LIST OF ESSENTIAL MEDICINES
http://mohfw.nic.in/WriteReadData/l892s/4767463099list.pdf
16
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INDIA

2011,

available

at

Government notifies new drug pricing policy, cheaper drugs on way, FINANCIAL EXPRESS, 13 December, 2012,
available
at
http://www.financialexpress.com/news/government-notifies-new-drug-pricing-policycheaper-drugs-on-way/1044845
17
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its market approval in India. While this exclusion may have been designed keeping the opportunity
for innovation for pharmaceutical companies, however, given the critical situation of HIV/AIDSs
medication, cancer drugs, tuberculosis etc., it is pertinent to have these drugs under price control
much before five years. Exception of 5 years will make accessibility to drugs extremely difficult.
This paper argues that this provision of the NLEM, 2012 contravenes the main objective of this
policy and in turn violates the Constitutional right to life and health of millions of people who
need these patented lifesaving drugs, especially the people living with HIV/AIDS (PHLAs). While
most of the Drug Pricing Policies in the past have been implemented in light of various objectives,
the 2012 National Pharmaceutical Policy is aimed mainly at making drugs affordable. The main
objective of the 2012 policy is to put in place a regulatory framework to ensure the availability of
essential drugs listed in the NLEM at affordable prices.19 Other measures for encouraging the
growth of the Pharmaceutical Industry and the development of new medicines, etc. will be adopted
by the Government at a later time.20
It is apparent form this provision that the Government has once again failed to address the most
pressing concerns relating to patented drugs in India. Patented drugs, especially the essential and
lifesaving drugs must be bought under price control. Many essential and lifesaving and ARV drugs
introduced in India after 2005 will be patent protected.21 Although patents are provisional and will
eventually expire, since ARV is a relatively new invention and will take some time before these
come off patent, many people living with HIV/AIDS will not be able to afford these drugs and
may die for lack of access to these antiretroviral drugs.22 People living with HIV/AIDS are likely
to develop resistance to first generation drugs and will need second-generation drugs soon. The
second and third generation drugs are mostly patented.23 The civil society has been filing patent

19

Supra note 17; supra note 2.

20

Supra note 2.

Harriet Gliddon, The end of the line for affordable HIV drugs? , available at
http://aglobalvillage.org/journal/issue3/global_health_and_development/hiv-drugs/ and Rachel Rizal,
Patents versus people: The battle over genericantiretroviraldrugs in India, 8 INT. J. HEALTH ETHICS & POL'Y 1,
15 (2008) available at http://ase.tufts.edu/tuftscope
21

Edwin Cameron, Patents and public health: principle, politics and paradox, 19 October, 2004 available at
http://www.law.ed.ac.uk/ahrc/script-ed/docs/cameron.asp#Causes
22

WHO
HIV
DRUG
RESISTANCE
REPORT,
2012
available
at
http://www.who.int/hiv/pub/drugresistance/report2012/en/index.html; Eben Harrel, New Study Raises
Concerns
About
HIV-Drug
Resistance,
TIME,
14
January
2010,
available
at
http://www.time.com/time/health/article/0,8599,1953718,00.html
23
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oppositions24 to block patenting of these lifesaving drugs. While some of these patent opposition
petitions were successful25 others were not. 26
In this scenario, if these patented drugs remain outside price control mechanism, it defeats the
purpose of this policy. It is pertinent to note that effective treatment for PLHA involves use of
multiple drugs in a process called “combination therapy.” The use of multiple drug therapies is
mostly considered better because it decreases the chance of developing drug-resistant strains of
HIV by cancelling out mutations against other drugs.27 Lack of access to one drug in a combination
therapy can impedes effective treatment. According to Médecins Sans Frontières (MSF), the fixeddose combination of d4T/3TC/NVP, a generic triple combination therapy costs 26 times less
than using the originator’s triple therapy.28 Though NVP and d4T were off-patent, Glaxo-SmithKline’s (GSK) patent on the ARV 3TC obstructed the availability of this drug.29
Further, the lack of availability of one patented drug in multiple combination therapy can
encourage the government to roll out drugs that may exclude the patented component. For
instance, the ARV 3TC was under patent protection, hence inaccessible in China. Therefore, the
government advocated a therapeutic regime which excluded 3TC.30

On 30 March 2006, the Manipur Network of Positive People (MNP), and the Lawyers' Collective
HIV/AIDS Unit filed an application opposing the patent application filed in the Kolkata patent office by
Glaxo Group Limited for Combivir, a fixed-dose combination of two AIDS drugs (zidovudine/lamivudine,
or AZT/3TC), Brazilian Interdisciplinary AIDS Association (ABIA) and the Indian NGO SAHARA
submitted a joint pre-grant opposition to the patent application of Tenofovir Disoproxil Fumarate in India,
The Indian Network for People Living with HIV/AIDS (INP+) and the Delhi Network of Positive People
filed an opposition to the patent application on the AIDS drug tenofovir disoproxil fumarate (TDF), see
also, Sangeeta Shashikant, Indian opposition to drug patents, TWN INFO SERVICE ON HEALTH ISSUES,
23 May, 2006, available at http://www.twnside.org.sg/title2/health.info/twninfohealth018.htm
24

India’s first post grant opposition was successful, the Intellectual Property Appellate Board (IPAB) has
revoked
the
patent
on
Roche’s
pegylated
interferon
alfa-2a
in
2012,
see
http://www.thehindubusinessline.com/companies/patent-on-roche-hepatitis-c-drugrevoked/article4057999.ece?homepage=true&css=print#> and the Cipla’s patent opposition application
was successfully against Pfizer in 2012, see http://www.business-standard.com/article/companies/ciplawins-patent-opposition-against-pfizer-s-cancer-drug-112100400199_1.html
25

See also Geeta Anand, Drug Makers Decry Indian Patent Law, WALL STREET JOURNAL, February 11,
2010, available at http://online.wsj.com/article/SB10001424052748703455804575057621354459804.html
26

King JR, Acosta EP, Chadwick E, et al, Evaluation of multiple drug therapy in human immunodeficiency virusinfected pediatric patients, 22 PEDIATR. INFECT. DIS. J. 3 (2003), available at
http://www.ncbi.nlm.nih.gov/pubmed/12634585
27

Cheri Grace, A Briefing Paper for DFID: Update on China and India and Access to Medicines, DFID HEALTH
RESOURCE CENTRE, 19 (November, 2005).
28

29

Ibid., at 4

30

Supra note 29, at 18
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It is clear that access to proper antiretroviral treatment is limited due to the high costs associated
with patented ARV drugs. With new waves of ARV drugs being produced to combat resistance,
access to proper treatment will only worsen as these new drugs are subject to patent protection.
Price control on patented drugs is essential because a medicine market is not a perfect market and
lack of price control will lead to exorbitant pricing.31 Increasingly, drugs in India are purchased
through private, out of the packet expenditure (79% according to a WHO study)32. Exemption
form price control for a period of five years is extremely unreasonable and is likely to adversely
impact the availability of lifesaving drugs. Even provisions like compulsory licensing, allow for
only a three year lock-in period which is under considerable criticism. One of the main reasons for
the three year lock-in period for compulsory licensing and the 5 year exemption for price control
is imposed mainly because there is an argument that patents represent one of the most important
incentives for commercial enterprises to undertake research and development.33 The proponents
of TRIPS argued that the 2005 amendments will encourage foreign investment, transfer of
technology and increase investment in research and development of neglected diseases. However,
the evidence has shown otherwise. There is also evidence to show that a strong patent regime does
not necessarily guarantee increased investment in Research and Development (R&D).34 Overall,
evidence shows that the implementation of stringent patent rights in developing countries has had
a negative impact on access to treatment, especially for PLHAs. 35 These time lags may result in
prolonged delay in accessing essential medications.

Constitutional Right to Health
The exemption on patented drugs under the NPP is in violation of the right to life under
Constitution of India. By recognizing that the fundamental right to life in Article 21 of the

REPORT OF THE COMMITTEE ON PRICE NEGOTIATIONS FOR PATENTED DRUGS,
Page 1 (Para1.1), available at
http://www.elsevierbi.com/~/media/Supporting%20Documents/Pharmasia%20News/2012/August/I
ndia%20Patent%20Drug%20Pricing%20Report.pdf
31

32

Id.

33

See, e.g., Jorge A. Goldstein & Elina Golod, Human Gene Patents, 77 ACAD. MED 12, 1315, 1323–24 (2002).

Why today’s R&D model doesn’t work for the needs of developing countries, MÉDECINS SANS FRONTIÈRES
(May, 2012) available at
http://www.msfaccess.org/sites/default/files/MSF_assets/Innovation/Docs/MedInno_Briefing_Globa
lConventionRD_ENG_2012Update.pdf
34

Dipika Jain and Rachel Stephens, The Struggle for Access to Treatment for HIV/AIDS in India, COMBAT
LAW PUBLICATION, 113 – 114 (2008).
35
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Constitution emphasizes the value of human dignity, the Supreme Court began to address the
importance of health as a fundamental right for Indian citizens. In addition to Article 47, the right
to health also has its genesis in Articles 3836, 39(e)37, 4138 and 48A39 of the Directive Principles. In
a series of cases, the Supreme Court40 has addressed the issue of healthcare as a fundamental right
and has imposed an obligation upon the state to take all steps to create conditions necessary for
good health, including facilities for basic curative and preventive health service. Lack of access to
essential and lifesaving drugs constitutes a violation of their right to the highest attainable standard
of health and therefore, the right to life.41 Courts around the world have relied on the rights to life
and health to ensure their respective Governments provide HIV/AIDS treatment to those in
need.42 In 2001, the Supreme Court of El Salvador in Jorge Odir Miranda Cortez v. Director of the
Salvadoran Institute of Social Security43 held that the El Savadorian Government must provide ARV
therapy and other medications that prevent the death and improve the quality of life of persons

State to secure a social order for the promotion of welfare of the people.- (1) The State shall strive to
promote the welfare of the people by securing and protecting as effectively as it may a social order in which
justice, social, economic and political, shall inform all the institutions of the national life.
(2) The state shall, in particular, strive to minimise the inequalities in income, and endeavour to eliminate
inequalities in status, facilities and opportunities, not only amongst individuals but also amongst groups of
people residing in different areas or engaged in different vocations
36

Certain principles of policy to be followed by the State: - The State shall, in particular, direct its policy
towards securing. (e) that the health and strength of workers, men and women, and the tender age of
children are not abused and that citizens are not forced by economic necessity to enter avocations unsuited
to their age or strength;
37

Right to work, to education and to public assistance in certain cases.- The state shall, within the limits of
its economic capacity and development, make effective provision for securing the right to work, to
education and to public assistance in cases of unemployment, old age, sickness and disablement, and in
other cases of undeserved want
38

Article 48A: Protection and improvement of environment and safeguarding of forests and wild life - The
State shall endeavour to protect and improve the environment and to safeguard the forests and wild life of
the country
39

In Consumer Education and Research Centres & Others. v. Union of India, (1995) 3 SCC 42, the Supreme Court
held that the right to health and medical aid to protect health is a fundamental right and that health implies
more than an absence of sickness. The Supreme Court in another case, State of Punjab and Others v. Mohinder
Singh Chawala, (1997) 2 SCC 83, reiterated that that the right to health is integral to the right to life and that
the Government has a constitutional obligation to provide healthcare facilities.
40

Hans V Hogerzeil, Essential medicines and human rights: what can they learn from each other?, 84(3) BULLETIN
OF
THE
WORLD
HEALTH
ORGANIZATION,
371-375 (2006),
available
at
http://www.who.int/bulletin/volumes/84/5/371.pdf
41

See Diego Serna Gómez v. Hospital Universitario del Valle; XXX v. Instituto de Seguros Sociales (ISS); Asociación
Benghalensis et al. vs. Ministerio de Salud y Acción Social;
42

Mr. Jorge Odir Miranda Cortez v. la Directora del instituto Salvadoreño del Seguro Social, Constitutional Court of
El Salvador, File n°348-99 (4 April 2001).
43
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living with HIV/AIDS.44 Similarly, In 1995, in XXX v. Instituto de Seguros Sociales (ISS)45, the
Columbian Constitutional Court, in 1997, in William García Álvarez v. Caja Costarricense de Seguro
Social46 and in 2000, the Argentinean Supreme Court in Asociación Benghalensis et al. vs. Ministerio de
Salud y Acción Social47, the respective Supreme Courts ruled that ARVs must be provided through
the Government’s social security scheme and public hospitals. The court based its decision on the
importance of the rights to life and health. Moreover, a Colombian appellate court recently held
that the Ministry of Health violated the right to health by not having Abbott comply with the
reference price for Kaletra. Resultantly, the Ministry imposed this requirement and the price of
Kaletra was reduced by 70 percent.48 Therefore, this policy of the government is violating the right
to health and right to life of people living with HIV/AIDS by not bringing affordable patented
drugs within the Price Control Policy of the government, which is being implemented with the
main aim of providing access to affordable lifesaving drugs.
Further in the on-going litigation in the Supreme Court, In All India Drug Action Network (AIDAN)
v. Union of India49, the Indian Supreme Court opined during the hearing in July 2012 that the
government must make every effort to provide access to lifesaving drugs to the citizens. Hence,
the patent exemption for 5 years must be reconsidered and the patented drugs must be brought
within the price control policy of the government before the actual notification of the Price drug
Order happens.
Conclusion
It is imperative for the government to reconsider the exemption clause for patented drugs under
the NPP, 2012 and allow for exemption of price control of patented drugs only for a very short
duration, if at all, and establish a robust mechanism by which prices can be fixed and these drugs
can be made accessible to save lives of several people living with HIV/AIDSs. The TRIPS
Agreement itself contains flexible mechanisms for balancing access to treatment with the
Mr. Jorge Odir Miranda Cortez v. la Directora del instituto Salvadoreño del Seguro Social, Constitutional Court of
El Salvador, File n°348-99 (4 April 2001).
44

Sentencia T-271/95, Exp. 62714, of Seventh Court of Revision of the Constitutional Court (June 23,
1995).
45

Mr. William Garcia Alvarez v. Caja Costarricense de Seguro Social, Constitutional court of Costa Rica, File 5778V-97, 23 September 1997.
46

Asociación Benghalensis et al. v. Ministerio de Salud y Acción Social, Supreme Court of Justice of Argentina,
Fallos 323:1339, 1 June 2000.
47

Public Citizen, Access Victories
http://www.citizen.org/Page.aspx?pid=5798
48

49

Writ Petition (civil) no(s). 423 of 2003.

and

Global

Kaletra

Campaign,

available

at
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preservation of intellectual property rights, such as compulsory licensing, parallel importation and
patent opposition procedures. However, these instruments will inherently be limited in enhancing
access to treatment because the successful implementation of each depends on several legal,
administrative and political factors. The litigation with Novartis50 and the unsuccessful patent
oppositions51 are some examples of such limitations that further delay or deny access to affordable
lifesaving drugs. . The Indian Government must reconsider this and deliberate on whether the best
interests of the country is allowing for an inclusive price control policy or struggle with other
restrictive or limiting provisions available.

50

Novartis AG v. Union of India (2007) 4 MLJ 1153.

51

Supra note 32.

